Table 3.
Multivariate analysis with Cox-proportional hazards regression to predict progression-free survival, cancer-specific survival, and overall survival.
| Progression-Free Survival a) | Cancer-Specific Survival b) | Overall Survival b) | ||||
|---|---|---|---|---|---|---|
| HR (95% CI) | p-Value | HR (95% CI) | p-Value | HR (95% CI) | p-Value | |
| Age | 1.08 (1.02–1.14) | 0.012 | 1.06 (1.01–1.12) | 0.022 | ||
| pT staging, ≥T3 | 3.58 (1.83–7.03) | <0.001 | 4.14 (1.16–14.69) | 0.028 | 4.04 (1.28–12.82) | 0.018 |
| pN staging, positive | 3.80 (1.82–7.92) | <0.001 | ||||
| Positive surgical margin | 2.64 (1.01–6.93) | 0.048 | ||||
| Presence of LVI | 4.2 (2.34–7.52) | <0.001 | 6.62 (2.06–21.24) | 0.002 | 8.88 (3.01–26.24) | <0.001 |
| Tumor grade III | 1.95 (1.05–3.62) | 0.034 | ||||
| Adjuvant chemotherapy | 0.35 (0.17–0.70) | 0.003 | 0.35 (0.11–1.13) | 0.080 | 0.25 (0.08–0.78) | 0.017 |
| Surgical approach | 0.580 | 0.970 | 0.699 | |||
| Robotic | reference | reference | reference | |||
| Open | 1.29 (0.71–2.33) | 1.12 (0.35–3.54) | 1.28 (0.45–3.61) | |||
| Laparoscopic | 1.45 (0.68–3.11) | 0.98 (0.22–4.40) | 0.77 (0.18–3.30) | |||
CI, confidential interval; CIS, carcinoma in situ; HR, hazard ratio; LVI, lymphovascular invasion. a) Adjusted with age, sex, Charlson comorbidity index, tumor size, tumor location, presence of carcinoma in situ. b) Adjusted with sex, Charlson comorbidity index, tumor size, tumor location, tumor grade, pN staging, margin status, presence of carcinoma in situ.